PORTLAND, Oregon, Feburary 1, 2024 Health Technology Innovations, Inc. (HTI) is excited to announce that Dr. Leah Frye, is joining HTI Advisory Board as Senior Advisor. Dr. Frye has 40 years of experience in drug discovery with an emphasis on medicinal and computational chemistry. Currently, she is the sole owner of LLFrye Consulting. In 2001, she co-founded the therapeutics group at Schrödinger. She led the group for 18 years and rose to the level of Vice President before returning to a focus on science as a senior drug designer and scientific advisor for the team. Under Dr Frye’s leadership, the Schrödinger Therapeutics Group worked with collaborators to put numerous compounds into clinical trials resulting in 2 FDA approved drugs to date. Recently, Schrödinger has developed its own internal drug discovery pipeline and currently has 2 compounds into clinical trials. Dr. Frye left Schrödinger in 2023 to form LLFrye Consulting. Prior to Schrödinger, she was a Principal Scientist at Boehringer Ingelheim Pharmaceuticals and before that she was an Associate Professor of Chemistry with tenure at Rensselaer Polytechnic Institute.
Dr. Frye holds a Ph.D. in Synthetic Organic Chemistry from The Johns Hopkins University and a B.S. Professional degree in Chemistry from the University of Idaho. She was an Individual Research Service Award postdoctoral fellow in the Department of Pharmacology and Molecular Sciences at The Johns Hopkins School of Medicine. Dr. Frye is an inventor on 20 issued US patents plus a number of recent patent applications.